The most common kidney cancer, clear cell Renal Cell Carcinoma (ccRCC) is closely associated with obesity. In fact, the "clear cell" variant of RCC is given this name due to large lipid droplets within the tumor cells. Although it is well appreciated that renal lipid metabolism is altered in ccRCC, the mechanisms driving this are not well understood. Leveraging a shotgun lipidomics approach we have identified a lipid signature for ccRCC that includes an increase in arachidonic acid-enriched phosphatidylinositols (AA-PI). In parallel, we found that ccRCC tumors have 3
Introduction
The most lethal and third most common urological cancer in the United States is clear cell renal cell carcinoma (ccRCC) (1) . Incident risk of ccRCC is closely associated with obesity (2), and ccRCC tumors are strikingly lipid laden compared to other malignancies (3) . In fact, the "clear cell" variant of RCC is given this name due to large intracellular lipid droplets that accumulate within the tumor cells, and in some cases ccRCC cells have a unilocular lipid droplet similar to what is seen in adipocytes (4) . Recently, several studies have demonstrated that altered prostaglandin levels may be involved in ccRCC growth and progression (5) (6) (7) , and intracellular lipid droplets may play a role in managing oxidative stress in the ccRCC tumor microenvironment (4) . Although it is well appreciated that renal lipid metabolism is altered in ccRCC, the mechanisms driving this are not well understood.
Phosphatidylinositols (PI) and closely related phosphoinositides (PIPs) are essential for life in eukaryotes (5) . These signaling phospholipids are commonly studied for their importance in cytokinesis, migration and cell polarity (6) (7) (8) . Although many studies have identified key signaling roles for PIPs in cancer progression (8) (9) (10) very little is known regarding whether compositional changes in the membrane PI pool, where PIP signaling lipids originate, is involved in ccRCC pathogenesis. Using acyl-CoAs as donors, phospholipids are formed by the de novo " Kennedy" pathway (12) and diversified by a remodeling pathway known as the Lands' cycle (13) . Although the major enzymes involved in the Kennedy pathway have been well characterized (12) , much less is known about enzymes involved in the Lands' cycle. A unique contributor to the membrane PI pool is membrane bound O-acyl transferase domain containing 7 (MBOAT7), an acyltransferase enzyme that selectively esterifies lysophosphatidylinositol (LPI) lipids to an arachidonyl-CoA to form the major PI species (38:4) in the inner leaflet of cell membranes (14, 15) . MBOAT7 is a unique contributor to the Lands' cycle, which is a series of phospholipasedriven deacylation and lysophospholipid acyltransferase-driven reacylation reactions that synergize to alter phospholipid fatty acid compositions, creating membrane asymmetry and 4 diversity. It is important to note that MBOAT7, unlike other lysophospholipid acyltransferses, only diversifies the fatty acid composition of membrane PI species and not phospholipids with other head groups (15, 16) Here we demonstrate that differential expression of MBOAT7 in advanced ccRCC is associated with survival, and MBOAT7 loss of function diminishes both proliferative and migratory properties of ccRCC cells. These data support the notion that limiting MBOAT7-driven PI diversification may hold therapeutic promise in ccRCC and potentially other cancers.
Results

MBOAT7 and its enzymatic product PI 36:4 are increased in ccRCC tumors.
To study the possible lipid related drivers of ccRCC, we took primary tumor biopsies with matched normal adjacent tissue samples from patients at the Cleveland Clinic, and performed untargeted lipidomics ( Figure 1A) . One of the most significantly increased lipids in the tumors compared to the non-tumor was PI 36:4 ( Figure 1B) . In parallel, expression of the LPI acyltransferase enzyme MBOAT7 was elevated ( Figure 1C) . Previous literature has demonstrated that MBOAT7 is the primary LPI acyltransferase enzyme involved in the enrichment of arachidonic acid into PI (AA-PI) (17) within the Lands' cycle of phospholipid remodeling ( Figure 1D ).
MBOAT7 increases with ccRCC severity and correlates with poor survival.
To explore the association of MBOAT7 expression within histological grade of ccRCC, we analyzed nephrectomy samples from initial surgical resection with age-, BMI-, and sex-matched patients. Interestingly, MBOAT7 expression increases with histological grade of ccRCC, particularly in grade IV cases (Figure 2A ). Furthermore, a commonly used ccRCC cell line Caki-1 has an increased expression of MBOAT7 similar to that of the grade 4 tumor samples (Supplementary Fig. 2 ). We next confirmed the increased MBOAT7 expression with histological grade in a validation cohort of patient samples. The Cancer Genome Atlas (TCGA) ccRCC cohort (KIRC) demonstrated a similar finding that MBOAT7 expression increases with histological severity (Figure 2B ). To assess the relationship between MBOAT7 mRNA expression and patient survival, we leveraged access to TCGA datasets and stratified patients into low versus high MBOAT7 mRNA levels. High MBOAT7 expression correlates with a poorer overall survival within histology matched cohorts or Stage III/IV patients ( Figure 2C ). These data provide evidence that MBOAT7 and enzymatic substrates or products may play a role in progression of ccRCC. Figure 5D ). These data suggest that MBOAT7-driven phospholipid remodeling is a critical determinate of epithelial to mesenchymal transition (EMT).
Discussion
Similar to other solid tumors, ccRCC is primarily driven by loss of key tumor suppressor such as von Hippel-Lindau (VHL) and activation of oncogenes (23) (24) (25) . Closely associated with these genetic alterations, lipid metabolic processes are dramatically altered in the ccRCC tumor microenvironment (3, 4, (26) (27) (28) (29) (30) (31) (32) (33) . In fact, the "clear cell" subtype gets its name from cholesterol ester-rich lipid droplets that accumulate in tumor cells (32, 33) . Although it has long been appreciated that ccRCC can be characterized as a "lipid metabolic disease" (34) (35) (36) , there is still incomplete understanding of which lipid metabolic targets are therapeutically tractable. This study to note that PLIN2 has been identified as a potential urinary biomarker of advance ccRCC (48, 49) , providing additional rationale to develop therapeutic strategies to intervene on this HIF2a-PLIN2 pathway. Collectively, all of these recently described lipid metabolic pathways altered in ccRCC provide potential targets for drug discovery. Here we expand this list to include MBOAT7 as a potential lipid metabolic target that is therapeutically tractable using a number of platforms.
Currently, there is a semi-selective small molecule MBOAT7 inhibitor (thimerosal), (50) which has shown some promise as a potential as a cancer therapeutic (51-53). However, thimerosal likely has many enzymatic targets, and additional structure-activity-relationship (SAR) drug discovery efforts are needed to find more selective inhibitors. Collectively, our work suggests that selective MBOAT7 inhibitors may hold promise to blunt the progression of metastatic ccRCC, and these findings may be broadly related to other cancer types where the PI3K-AKT-mTOR axis is hyperactive.
Methods
Lipidomic Profiling of ccRCC.
To understand alterations across a wide range of structurallydistinct lipids we developed a shotgun lipidomics method for measurement of multiple lipid species as previously described (54) . All the internal standards were purchased from Avanti Polar The peak intensities for each identified lipid, across all samples were normalized against an internal standard from same lipid class for the semi-quantitation purpose. and 866 à 281 for internal standard PI-34:1-d31. Data Analysis: Software Labsolutions LCMS was used to get the peak area for both the internal standards and LPI and PI species. The internal standard calibration curves were used to calculate the concentration of LPI and PI species in the samples. All plasma LPI and PI species were normalized to the PI-34:1-d31 internal standard,
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while all tissue LPI species were normalized to the 17-1 LPI internal standard and all tissue PI species were normalized to the PI-34:1-d31 internal standard.
RNA isolation and quantitative real time-PCR. Total RNA was isolated using an RNeasy or Trizol isolation methods using manufacturer's recommendations (Qiagen and Thermo Fisher). RNA concentrations were quantified using a Nanodrop 2000. mRNA expression levels were calculated based on the DD-CT method. qPCR was conducted using the Applied Biosystems 7500 RealTime PCR System. Primers used for qPCR are available on request. populations. The chromatographs from the clonal populations were screened for editing using the previously described method (56) . These populations were then validated using targeted mass spectrometry for LPI and PI lipids, mRNA abundance by qPCR, and Western blotting. 
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